Aurelio Teleman Selected Research

Biomarkers (Surrogate Marker)

1/2023

Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aurelio Teleman Research Topics

Disease

2	Neoplasms (Cancer) 01/2023 - 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2023
1	Insulin Resistance 01/2022
1	Type 2 Diabetes Mellitus (MODY) 01/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022
1	Diabetes Mellitus 04/2019
1	Diabetes Complications 04/2019

Drug/Important Bio-Agent (IBA)

2	Pyruvaldehyde (Methylglyoxal)IBA 01/2022 - 04/2019
1	AntioxidantsIBA 01/2023
1	Biomarkers (Surrogate Marker)IBA 01/2023
1	Histones (Histone)IBA 01/2022
1	LipidsIBA 01/2022
1	Urokinase Plasminogen Activator ReceptorsIBA 01/2022
1	imidazoloneIBA 01/2022
1	AlbuminsIBA 01/2022
1	CreatinineIBA 01/2022
1	acetolIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Oxygen (Dioxygen)IBA 04/2019
1	Glucose (Dextrose)FDA LinkGeneric 04/2019

Therapy/Procedure

1	Diet Therapy (Therapy, Diet) 01/2022
1	Mediterranean Diet 01/2022